Stabilisation of ATF4 protein with proteasomal degradation inhibitor BTZ, which has been applied clinically for the treatment of multiple myeloma and other cancers, might be a rational strategy to improve chemotherapeutic efficacy in gastric cancer. This evidence concerns the gene ATF4 and cancer.